Oculex Pharmaceuticals
Signal active
Organization
Contact Information
Overview
Oculex Pharmaceuticals is an ophthalmic drug delivery company that is focused on the development of therapeutic products for the treatment of sight-threatening diseases.
Oculex Pharmaceuticals develops Posurdex, a biodegradable release implant that delivers dexamethasone to the targeted disease site at the back of the eye.
Oculex Pharmaceuticals was acquired by Allergan in November 2003.
Oculex Pharmaceuticals was founded in 1989 and is based in Sunnyvale, California.
About
Industries
Biotechnology, Health Care, Pharmaceutical
Founded
1989
Employees
101-250
Headquarters locations
United States, North America
Social
N/A
Profile Resume
Oculex Pharmaceuticals headquartered in United States, North America, operates in the Biotechnology, Health Care, Pharmaceutical sector. The company focuses on Biotechnology and has secured $600.0M in funding across 12 round(s). With a team of 101-250 employees, Oculex Pharmaceuticals is actively contributing to advancements in Biotechnology. Their latest funding round, Series B - Oculex Pharmaceuticals, raised $50.0M. Discover more about their projects, partnerships, and impact on our platform.
Employees
N/A
Funding Rounds
Funding rounds
1
Investors
6
Lead Investors
0
Total Funding Amount
$50.0M
Details
1
Oculex Pharmaceuticals has raised a total of $50.0M in funding over 1 rounds.
| Announcement date | Transaction name | Number of Investors | Money raised | Lead Investor |
|---|---|---|---|---|
| 2002 | Early Stage Venture | 50.0M |
Investors
Oculex Pharmaceuticals is funded by 8 investors.
| Investor Name | Lead Investor | Funding Round | Partners |
|---|---|---|---|
| Bay City Capital | - | FUNDING ROUND - Bay City Capital | 50.0M |
| Vivo Capital | - | FUNDING ROUND - Vivo Capital | 50.0M |
| Oculex Pharmaceuticals | - | FUNDING ROUND - Oculex Pharmaceuticals | 50.0M |
| Aisling Capital | - | FUNDING ROUND - Aisling Capital | 50.0M |
Recent Activity
There is no recent news or activity for this profile.